Efficacy

Efficacy of Monjuvi (tafasitamab-cxix) for Lymphoma

Monjuvi (tafasitamab-cxix) is a CD19-directed cytolytic antibody indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). This medication is not intended for the treatment of patients with DLBCL who are eligible for autologous stem cell transplant (ASCT). The efficacy of Monjuvi, in combination with lenalidomide, was primarily demonstrated in a multicenter, single-arm trial that included patients with relapsed or refractory DLBCL. The overall response rate (ORR), which includes complete and partial responses, was observed to be significant, providing a therapeutic option for patients who have limited treatment choices.

The clinical trial results showed that the combination of Monjuvi with lenalidomide led to a marked improvement in ORR compared to historical controls of patients treated with lenalidomide alone. The duration of response (DOR) for patients who achieved a response was also notable, with a significant proportion of these patients maintaining their response at a median follow-up, indicating the potential for durable remissions in this patient population.

Efficacy of Glofitamab (glofitamab-gxbm) for Lymphoma

Glofitamab (glofitamab-gxbm) is an investigational bispecific T-cell engager antibody being studied for the treatment of various types of non-Hodgkin lymphoma, including DLBCL. Glofitamab works by simultaneously binding to CD20 on B-cells and CD3 on T-cells, thereby bringing the T-cells into close proximity with the cancerous B-cells to induce cell death. While still under clinical investigation, glofitamab has shown promise in early clinical trials, demonstrating efficacy in patients with relapsed or refractory B-cell lymphomas.

In these trials, patients who had previously been treated with multiple lines of therapy, including those who had relapsed after CAR T-cell therapy, were observed to respond to glofitamab. The reported data indicated that a significant number of patients achieved a complete response, which is a highly encouraging outcome for this heavily pre-treated patient group. The duration of response and progression-free survival rates for patients responding to glofitamab are areas of active investigation, with ongoing studies aiming to provide more comprehensive efficacy data.